Evidence map›Paper›PMID 42273648›Full record

ArticleNuclear medicine and molecular imaging2026

Optimizing [

M H Sanad, Safaa B Challan, A Massoud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

M H SanadLabeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.
Safaa B ChallanLabeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.ORCID 0000-0002-2711-3254
A MassoudNuclear Chemistry Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the potential of Tamsulosin hydrochloride, a selective α1-adrenoceptor antagonist, as a tumor-targeting ligand when labeled with Technetium-99 m [⁹⁹ᵐTc] for use as a novel radiopharmaceutical. This study aims to develop and evaluate the [⁹⁹ᵐTc]Tc-Tamsulosin complex for enhanced tumor imaging and improved diagnostic accuracy in oncology. Methods: The radiolabeling process was optimized using 0.6 mg of tamsulosin, 75 µg of SnCl Results: The [⁹⁹ᵐTc]Tc-Tamsulosin complex achieved a radiochemical purity of 97.5 ± 0.12% and maintained in vitro stability in serum and PBS above 87 ± 0.22% after 24 h. In vivo evaluation revealed peak tumor uptake (T) of 5.2 ± 0.02% ID/g and normal muscle (NT) uptake of 0.98 ± 0.01% ID/g at 2 h post-injection, with a target-to-non-target ratio of 5.3. Renal clearance was prominent, with kidney uptake of 16 ± 0.24% ID/g and urinary excretion reaching 25 ± 1.37% ID/g at 3 h. Conclusion: The [⁹⁹ᵐTc]Tc-Tamsulosin complex demonstrates high radiolabeling efficiency, stability, and selective tumor accumulation, supporting its potential as a promising radiopharmaceutical for accurate tumor imaging. These findings highlight its value in advancing nuclear medicine oncology diagnosis.

Indexed as

In-vivo evaluationRadiolabeling optimizationTamsulosin hydrochlorideTechnetium-99m [99mTc]Tumor imaging

Identifiers

PMID42273648
PMCPMC13247024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.